NEW ORLEANS -- A fixed-dose combination of novel amylin analog cagrilintide and semaglutide, given once weekly, lowered blood glucose and weight in various populations with type 2 diabetes.
The combination injectable, dubbed CagriSema, performed well at doses of 2.4 or 1.0 mg of each drug across three phase III double-blind REIMAGINE studies presented at the American Diabetes Association (ADA) annual meeting.
In the REIMAGINE I trial among patients early in the course of type 2 diabetes, the higher and lower CagriSema doses led to 1.8- and 1.5-percentage point drops in HbA1c from baseline to week 40, corresponding to estimated treatment differences over placebo of 1.7 percentage points and 1.3 percentage points (both P<0.0001).
Change in body weight also favored CagriSema over placebo in REIMAGINE 1, with an estimated treatment difference of 12.4 percentage points and 10.4 percentage points for higher and lower doses, respectively (both P<0.0001), reported Vanita Aroda, MD, of Brigham and Women's Hospital and Harvard Medical School in Boston.
Traditional cardiometabolic risk factors, including blood pressure and C-reactive protein, also improved, and there were no new safety signals beyond what has been seen previously with the class, said Aroda at a press conference.
